Alteogen Inc.
196170
Kedudukan dalam Saham
#1863
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Harga Saham
$163.88
Modal Pasaran
$11.41B
Perubahan (1 hari)
1.72%
Perubahan (1 tahun)
-46.19%
Negara
KR
Perdagangan Alteogen Inc. (196170)
Kategori
Healthcare
Margin Operasi untuk Alteogen Inc. (196170)
Margin Operasi pada October 2026 TTM: 47.16%
Menurut laporan kewangan dan harga saham terkini Alteogen Inc., margin operasi semasa (TTM) ialah 47.16%. Pada akhir 2023, margin operasi syarikat ialah -10.09%.
Sejarah Margin Operasi untuk Alteogen Inc. dari 2012 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | 47.16% | 90.93% |
| 2024 | 24.70% | -344.80% |
| 2023 | -10.09% | -90.10% |
| 2022 | -101.97% | 160.06% |
| 2021 | -39.21% | 27,907.14% |
| 2020 | -0.14% | -98.18% |
| 2019 | -7.70% | -86.23% |
| 2018 | -55.90% | 9.61% |
| 2017 | -51.00% | -35.50% |
| 2016 | -79.07% | -3,117.94% |
| 2015 | 2.62% | -74.51% |
| 2014 | 10.28% | -62.39% |
| 2013 | 27.33% | -34.80% |
| 2012 | 41.92% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -99.18% |
US
|
|
| -149.01% | -103.16% |
US
|
|
| 25.57% | -99.46% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.39% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.